Janus Henderson Group plc Reports 6.8% Stake in BridgeBio Pharma, Inc. (BBIO) via Schedule 13G/A

Janus Henderson Group plc filed a Schedule 13G/A on May 15, 2026, reporting a 6.8% stake in BridgeBio Pharma, Inc. (BBIO). As of the event date on March 31, 2026, the firm beneficially owns 13,179,013 shares of common stock. This filing represents an increase from a previously reported 0.0% position, though it is marked as an amendment (Amendment No. 1). Janus Henderson Group plc serves as the ultimate parent company for several SEC-registered investment advisers, including Janus Henderson Investors US LLC and Janus Henderson Investors UK Limited. These subsidiary asset managers exercise shared voting and dispositive power over the shares on behalf of various managed portfolios, such as investment companies and institutional accounts. The filing indicates that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. No individual managed portfolio holds more than 5% of the outstanding common stock.